In breast cancer, CEBPD reportedly links to interleukin-6 and hypoxia-inducible factor 1 signaling to promote cancer stem cell-associated phenotypes [32], which is a well-known factor correlated with drug resistance [33]. Here, IL6 is linked to breast cancer.